A map of the nonclinical safety package: what ICH M3(R2) requires before first-in-human dosing
Before a new medicine is given to a human for the first time, regulators expect a defined set of nonclinical
The 3Rs in practice: where in vitro models like macrophage assays fit in early safety assessment
The 3Rs, Replacement, Reduction and Refinement, were proposed by William Russell and Rex Burch in 1959 (Russell & Burch, 1959)
Interactions as safety signals: how DDI case reports feed pharmacovigilance
Some of the best-known drug withdrawals were not about a single drug. They were about combinations.
Pharmacogenomics at the counter: when a patient's genes change the interaction picture
Most interaction checks look at drug against drug. Pharmacogenomics adds a third factor: the patient's own genes.
Five drug interactions I check for every day in a Swiss community pharmacy
Interaction software in a pharmacy flags dozens of alerts a day. Most are minor. The skill lies in recognising the
Why ADRs are under-reported, and what pharmacists can do about it
Spontaneous reporting is still one of the most important ways to detect new drug safety problems. Yet most suspected adverse drug reactions are never reported.
What makes a valid ICSR? The four minimum criteria, explained with pharmacy examples
Every pharmacovigilance system is built on one unit of information: the individual case safety report, or ICSR. Before a case can be assessed, coded or reported to an authority, someone has to decide whether it is valid.